What to Expect When Increasing Your Wegovy Dose

What the STEP trial data showed about tolerability during titration

The STEP 1 trial, published in the New England Journal of Medicine, followed adults on semaglutide 2.4 mg for 68 weeks. The trial's titration phase ran from 0.25 mg upward, and the data showed that gastrointestinal adverse events were most concentrated during dose escalation rather than at steady-state maintenance. That pattern is not unique to the trial setting, it is the clinical reality most people on Wegovy encounter.

The mechanism is straightforward. Semaglutide slows gastric emptying and damps the brain's hunger signals. Each time the dose rises, those effects intensify before the body recalibrates. The result is usually a few days of reduced appetite, some nausea, and occasionally looser stools. For most people these sensations peak around day two or three after the new pen and are noticeably better by the end of the first week.

What the trial also showed is that the majority of participants did not discontinue because of GI effects. The stepped schedule exists precisely to keep tolerability manageable. If you are considering what the journey from first pen to maintenance looks like, the first dose experience gives useful context for what the pattern repeats (in milder form) at each subsequent step.

The specific changes to watch for at each step up

The licensed schedule moves in roughly four-weekly stages: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and then 2.4 mg as the standard maintenance dose. With the MHRA's April 2026 approval of a dedicated 7.2 mg pen, a further step now exists for eligible adults, though availability at any given dose is confirmed at your clinical review rather than assumed in advance.

At the lower doses (0.25 mg to 0.5 mg) most people report the mildest symptoms. The step to 1.0 mg is where appetite suppression becomes noticeably stronger for many, and nausea tends to be more pronounced in the first few days. The 1 mg transition is the one our prescribers hear about most, and the practical advice is consistent: eat to a smaller plate, lean toward plain foods in the first week, and avoid high-fat meals that slow gastric emptying further.

Moving to 1.7 mg and then 2.4 mg follows the same pattern. Each step-up resets a short adaptation window. If the 1.7 mg step interests you specifically, there is a detailed look at what to expect at that dose. The full dose range, including the newer 7.2 mg option, is covered on the Wegovy doses overview.

Injection-site reactions (redness, mild swelling or itching at the injection point) can also reappear briefly after a step-up. Rotating sites between the abdomen, thigh and upper arm reduces this. The pen arrives in plain, unbranded packaging via DPD, and there is a tracking notification so you know exactly when it will land; once it is in the fridge, keeping it at 2–8°C until the day you inject is important.

When to stay at your current dose rather than step up

Not everyone moves through the titration at exactly the same pace, and that is by design. NHS England's guidance on weight management injections is clear that tolerability, not the calendar, should drive the decision to increase. If side effects from a dose step are still present and disruptive at week three, remaining at the current dose for another four weeks is a clinically appropriate choice.

The signals that suggest a pause rather than a push include persistent nausea that is affecting your ability to eat adequate protein, vomiting on most days, or significant fatigue that is not easing. None of these mean treatment has failed. They mean the titration needs more time. A slower path to maintenance is preferable to abandoning treatment because a step-up was rushed.

There are also symptoms that require prompt medical attention, not just a message to your prescriber. Severe, persistent abdominal pain that extends toward the back (with or without vomiting) should be assessed urgently, as this can be a sign of pancreatitis. The MHRA flagged acute pancreatitis as a known, if infrequent, risk with GLP-1 medicines in a Drug Safety Update issued in January 2026. Any suspected side effects, including those following a dose increase, can be reported at the MHRA Yellow Card scheme.

For a fuller account of what drives the timing decision, the page on when to increase your Wegovy dose goes through the clinical criteria in detail. And if you are weighing up Wegovy against other licensed options, a broader look at weight-loss treatment routes may be useful before your next clinical review.

Practical steps that make a dose transition easier

Small, consistent habits do more than people expect during a transition week. Eating slowly and stopping before fullness (the appetite signal is stronger after a step-up, so it arrives sooner than usual) prevents the nausea that comes from overfilling a stomach that is already emptying more slowly. Protein at every meal matters: semaglutide reduces overall intake, and if that reduction falls mainly on protein-rich foods, muscle loss becomes a concern over months.

Hydration is equally practical. Nausea reduces the urge to drink, but dehydration can make nausea worse and, in cases where vomiting or diarrhoea is present, can become clinically significant. Plain water, diluted squash or clear broth all count.

Ginger (whether as tea, capsules or ginger biscuits) has reasonable evidence behind it for mild nausea and is widely used by people on GLP-1 treatment; it is not a prescription item, and it does not interact with semaglutide. The guide to increasing your Wegovy dose covers the practical side of this in more detail.

If you are at an early stage and want to understand how the whole journey fits together, reading about how Wegovy works provides the wider picture. And when you are ready to start your free consultation, our prescribers review every application the same day, a real clinician, not an automated system, reads your details before any decision is made. Start your free consultation.